Capricor Shares Rise as Longer-Term Deramiocel Data Enter FDA Review

Key Points

• Capricor shares rose in early trading Tuesday after a World Muscle Society poster on 24-month deramiocel data became available.
• The analysis follows patients from the Phase 3 HOPE-3 trial and its open-label extension; 82 of the 106 originally randomized patients reached 24 months.
• Capricor included the longer-term analyses in a major amendment to its Biologics License Application ahead of a November 22 FDA target decision date.
• HOPE-3 met its 12-month primary endpoint, but an FDA advisory committee voted 9–3 in July that the evidence did not support effectiveness for Duchenne-related cardiomyopathy.
• The supplied account describes the 24-month analyses but does not provide their numerical efficacy results.

Capricor Therapeutics (NASDAQ: CAPR) drew investor attention as longer-term data on deramiocel, its experimental Duchenne muscular dystrophy treatment, became available through the 2026 World Muscle Society congress. The results matter because the FDA is reviewing the 24-month analyses as part of Capricor’s application—not because the poster itself changes deramiocel’s regulatory status.

HOPE-3 Follow-Up Examines Earlier Versus Delayed Treatment

In the first 12 months of HOPE-3, patients received either deramiocel or placebo. Eligible participants could then enter an open-label extension in which they received deramiocel. The 24-month analysis includes 40 patients originally assigned to deramiocel and 42 originally assigned to placebo.

This delayed-start approach lets researchers examine whether patients treated from the beginning retain an advantage over those who start a year later. The poster also compares outcomes with Duchenne natural-history data. Those comparisons may add context, but they are not the same as maintaining a randomized placebo group for the full two years.

Earlier Trial Result Supports Application, but FDA Risk Remains

The randomized 12-month HOPE-3 trial met its primary endpoint: deramiocel slowed deterioration in upper-limb function by 54% versus placebo on the Performance of the Upper Limb 2.0 scale (p=0.03).

Regulatory uncertainty remains. In July, an FDA advisory committee voted 9–3 that the available evidence did not support deramiocel’s effectiveness for cardiomyopathy in Duchenne patients. That vote addressed the cardiomyopathy question, not deramiocel’s entire benefit-risk profile, and the FDA is not bound by it.

Investor Takeaway: Watch the FDA Decision and Full Data

For CAPR investors, the November 22 FDA target date is the central near-term milestone. The inclusion of 24-month data in the application gives regulators longer-term evidence to assess, but it does not indicate how they will decide. Investors should also look for the actual 24-month outcome figures before drawing conclusions about the size or durability of any treatment effect.

A scheduled October 3 presentation will address HOPE-3 skeletal-muscle and cardiac evidence. Capricor is separately presenting preclinical research on its StealthX exosome technology for Duchenne muscular dystrophy and Pompe disease; neither program is a clinical-stage substitute for the deramiocel regulatory decision.